dilazep has been researched along with Cardiac Failure in 1 studies
Dilazep: Coronary vasodilator with some antiarrhythmic activity.
dilazep : A member of the class of diazepanes that is 1,4-diazepane substituted by 3-[(3,4,5-trimethoxybenzoyl)oxy]propyl groups at positions 1 and 4. It is a potent adenosine uptake inhibitor that exhibits antiplatelet, antianginal and vasodilator properties.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Pollter, J | 1 |
| Schnitker, J | 1 |
1 trial available for dilazep and Cardiac Failure
| Article | Year |
|---|---|
[Therapy of coronary heart disease using Cormelian-Digotab: influence of the duration of therapy. 2. Field study by 107 physicians].
Topics: Azepines; Clinical Trials as Topic; Coronary Disease; Digoxin; Dilazep; Drug Combinations; Heart Fai | 1976 |